Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Dartmouth Cancer Center, Lebanon, NH, USA.
Dartmouth-Hitchcock Medical Center, One Medical Center Drive, HB-7936, Lebanon, NH 03756, USA.
Cancer Metastasis Rev. 2023 Mar;42(1):87-98. doi: 10.1007/s10555-023-10081-7. Epub 2023 Jan 25.
While anti-cancer drug treatments are often effective for the clinical management of cancer, these treatments frequently leave behind drug-tolerant persister cancer cells that can ultimately give rise to recurrent disease. Such persistent cancer cells can lie dormant for extended periods of time, going undetected by conventional clinical means. Understanding the mechanisms that such dormant cancer cells use to survive, and the mechanisms that drive emergence from dormancy, is critical to the development of improved therapeutic strategies to prevent and manage disease recurrence. Cancer cells often exhibit metabolic alterations compared to their non-transformed counterparts. An emerging body of evidence supports the notion that dormant cancer cells also have unique metabolic adaptations that may offer therapeutically targetable vulnerabilities. Herein, we review mechanisms through which cancer cells metabolically adapt to persist during drug treatments and develop drug resistance. We also highlight emerging therapeutic strategies to target dormant cancer cells via their metabolic features.
虽然抗癌药物治疗通常可有效用于癌症的临床治疗，但这些治疗方法常常会留下具有药物耐受性的休眠癌细胞，而这些细胞最终可能导致疾病复发。这些休眠的癌细胞可以潜伏很长时间，常规的临床手段通常无法检测到它们。了解休眠癌细胞用于存活的机制，以及导致其从休眠中苏醒的机制，对于开发预防和管理疾病复发的改进治疗策略至关重要。与未转化的细胞相比，癌细胞通常表现出代谢改变。越来越多的证据支持这样一种观点，即休眠癌细胞也具有独特的代谢适应性，这可能为治疗提供有针对性的弱点。本文综述了癌细胞在药物治疗过程中通过代谢适应以保持存活并产生耐药性的机制。我们还强调了通过其代谢特征靶向休眠癌细胞的新兴治疗策略。
